TUMOR-GROWTH MODULATION BY A MONOCLONAL-ANTIBODY TO THE EPIDERMAL GROWTH-FACTOR RECEPTOR - IMMUNOLOGICALLY MEDIATED AND EFFECTOR CELL-INDEPENDENT EFFECTS

  • 15 July 1987
    • journal article
    • research article
    • Vol. 47  (14) , 3692-3696
Abstract
A monoclonal antibody of IgG2a isotype (425) is described that reacts with the epidermal growth factor receptor on human cells of different tissue origins. Monoclonal antibody 425 mediates tumor cytotoxicity in vitro using mouse and human effector cells and suppresses in vivo tumor cell growth of epidermoid (A 431) and colorectal (SW 948) carcinoma-derived cell lines. The tumoricidal effects in vitro are proportional to the antigen density on target cells. At concentrations higher than 1 nM, monoclonal antibody 425 inhibits growth of epidermal growth factor receptor-bearing A 431 cells, showing an epidermal growth factor-like agonist activity on the growth properties of these cells. A 431 cultures grown in the presence of growth-inhibiting doses of antibody or epidermal growth factor reveal a clear decrease of the relative number of cells in S phase. Additionally, cells treated with the antibody show a decrease of G2-M phase cells in some, but not all, cultures tested.

This publication has 31 references indexed in Scilit: